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Background: Lung carcinoid tumor and low grade glioma are two uncommon malignancies.
Patients and methods: We report the case of 24-year-old man who presented with respiratory disease. Imaging
investigations showed a right lung tumor and histological analysis confirmed a typical carcinoid tumor. As part of
initial staging, brain MRI revealed an asymptomatic right frontal lesion. First, a right pulmonary lobectomy was
performed without adjuvant treatment. In second time, brain tumorectomy was performed. Histological
examination confirmed the diagnosis of low grade glioma (LGG). The patient remained in complete remission
2.5 years after the initial diagnosis.
Results: This is the first case reporting the association between LGG and lung carcinoid tumor, while no association
between LGG and a systemic tumor have been published to date. Association of lung carcinoid tumor with other
malignant diseases has been reported but remained uncommon. Only minimal data support a potential molecular
common origin.
Conclusion: This exceptional association may be fortuitous. However, their concomitant diagnoses suggest a
potential association between both rare diseases. A genetic susceptibility remains possible.Background
Carcinoid bronchopulmonary tumors represent approxi-
mately 1 to 2% of all lung neoplasms. Low grade glioma
(LGG) are rare, diffuse, slow-growing, primary neuroec-
todermal tumors that occur in the central nervous sys-
tem. In this report, we present the first association
between LGG and lung carcinoid tumor. We also per-
formed a comprehensive review of the literature on the
association between LGG or carcinoid tumor, and sys-
temic malignancies.Case presentation
A 24-year-old man presented in September 2009 with
respiratory symptoms including cough and hemoptoic
expectorations, without altered general status. Past med-
ical history was restricted to Oto-Rhino-Laryngological
viral infections without smoking, alcohol, or asbestos* Correspondence: emeline.tabouret@gmail.com
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reproduction in any medium, provided the orexposure. Clinical observation was not relevant with
normal respiratory and neurological examinations.
Thoracic radiography showed a mass in the right lung.
Computed tomography (CT) confirmed a lung tumor
(56 mm) in the right superior lobe associated with me-
diastinal lymph node involvement without visceral me-
tastasis. First, lung fibroscopy was performed. It was
complicated by massive hemoptysis. Histological ana-
lysis concluded a diagnosis of typical carcinoid tumor.
Positron emission tomography was moderate positive
(Standardized Uptake Value = 4) and octreoscan pre-
sented an intensive fixation for lesions previously
described on the CT scan (Figure 1). Both examinations
were negative for brain lesions. The plasmatic rate of
insulinemia, gastrinemia, chromogranine A, cyfra21 and
Neuron-Specific Enolase (NSE) were normal. The rate
of plasmatic serotonin was 365 μg/L (normal: 100 to
300 μg/L). The plasmatic \ hCG and β-hCG levels were
normal. To complete disease evaluation, brain magnetic
resonance imaging (MRI) was performed and revealed a
right frontal infiltrative lesion that exhibited hyposignal
T1 and hypersignal in T2 and flair sequences, with noal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Lung TEP scanner (top) and octreoscanner (bottom).
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with an LGG (Figure 2).
Lung surgery consisted of a right superior lobectomy
with a resected tumor that measured 5 cm. Lymph node
involvement was restricted to one of the 16 explored
nodes. Definitive histology confirmed a typical carcinoid
tumor pT3N1M0 R0 (Stage IIIA). After multidisciplinary
consultation no adjuvant treatment was indicated.
On subsequent surgery, gross total resection of the
brain tumor was performed. Anatomopathologic exam-
ination concluded a diagnosis of grade II oligoastrocy-
toma. Further immunohistochemical and molecular
analyses identified expression of p53, lack of MGMTFigure 2 Brain magnetic resonance imaging (MRI): T1 gadolinium seq(O(6)-methylguanine-DNA methyltransferase) promoter
methylation, absence of IDH (Isocitrate Dehydrogenase)
mutation and no amplification of EGFR (Epidermal
Growth Factor Receptor). Using Fluorescence In Situ
Hybridization technique, no 1p19q codeletion was
detected. An adjuvant treatment with radiotherapy
(60Gy) and concomitant temozolomide (75mg/m2 per
day, five days per week, during 6 weeks) was per-
formed. At present, patient is routinely follow-up and
complete remission is maintained 2.5 years after the
initial diagnosis.
Oncogenetic examination was proposed to the patient.
It showed an atypical aggregation of oncologic diseases
but did not find genetic abnormality or hereditary risk
factor. No additional biological investigation was per-
formed, as this tumor association did not refer to a
known genetic syndrome. Only blood conservation was
realised.
Discussion
To our knowledge, this is the only reported case of an
association between a carcinoid tumor and glioma. This
exceptional association may be fortuitous. However their
concomitant diagnoses may suggest a potential relation-
ship between these two both rare tumors.
Carcinoid tumours are a unique class of malignancies
capable of producing hormones identical to those from
the nervous system [1]. Its representatives are found in
the lung, gastrointestinal tract, skin, thyroid, thymus,
pancreas, biliary and urogenital tracts. Lung carcinoid
tumors tend to occur at a younger age as in our patient
[2]. Survival is generally good, especially in patients with
early stage disease, with reported 5-year survival rates of
44 to 97% [3,4].
Low grade gliomas are tumors that exhibit glial dif-
ferentiation without aggressive findings (angiogenesis).uence (left) and T2 sequence (right).
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some tumor cells show astrocytic differentiations while
others show oligodendroglial differentiations [5]. No as-
sociation between low grade glioma and systemic tumor
were reported.
Association of carcinoid tumors with other malignant
diseases is uncommon. Rare isolated cases have been
reported with association between carcinoid tumors and
other carcinomas (gastric [6], renal [7], colorectal, and
breast carcinoma [8]) [9]. Two cases of synchronous pul-
monary carcinoid tumor and non-Hodgkin’s lymphoma
have been described [10]. Carcinoid tumors of the lung
were also rarely described in the multiple endocrine neo-
plasia type 1 (MEN1) [11]. MEN1 is an autosomal dom-
inant genetic disorder first described in 1903 by Jacob
Erdheim, which has been associated with a combination
of more than 20 endocrine and nonendocrine lesions.
The prevalence of carcinoid bronchial tumors among
MEN1 is only 2%. Tumors associated with MEN1 in-
clude meningiomas and ependymomas but not glioma
[11]. So, no evidence of clinical and genetic association
between primary brain and carcinoid tumors was found.
Two molecular analyses showed correlation between
LGG and carcinoid tumors. The first reported that
astrocytomas could share N-CAM-related antigens with
small lung carcinomas. This biological observation could
support a relationship or potential common origin be-
tween neural and neuroendocrine tumors [12]. A second
publication compared gene expressions of small cell lung
cancers, pulmonary carcinoid tumors and oligodendro-
gliomsa using high-density cDNA arrays [13]. They
found similarity of gene expression among carcinoid
tumors and oligodendrogliomas, suggesting that pul-
monary carcinoids are related to neural crest-derived
brain tumors. These molecular similarities and pre-
sumed common tumoral origin of both carcinoid and
LGG raise the possibility of a unique molecular abnor-
mality driving the development of the two tumors in our
patient. However, explorations of genetic causes in this
patient remain unsuccessful to date.Conclusion
Ours is the first case reporting the association between
low grade glioma and lung carcinoid tumor. The occur-
rence of these tumors might be an as yet undescribed
association that is more than fortuitous. A genetic sus-
ceptibility remains possible.Consent
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